Fig 1.
Methodology flow diagram for the validation or novel transport modes to assure quality of medicines, building on UNICEF’s drone delivery decision model [26].
Fig 2.
Sample information and preparation process.
Fig 3.
(a) Cargo bay with base vibration sensor mounted (held in position by red tape); (b) Loaded 18 L Versapak; (c) Versapak base sensor; (d) Versapak with insulated cool packs, sensors, samples.
Table 1.
Packaging and sensor arrangements for each trial.
Fig 4.
Schematic of forced vortexing experiment used in validating the analysis methods.
Fig 5.
Skylift V50 (Mugin 5 Pro) VTOL drone used in both trials.
Fig 6.
Flight path of the test flight in the second trial, based at the military base at Thorney Island.
Distance flown was 10.9km. Base map and data from OpenStreetMap and OpenStreetMap Foundation.
Fig 7.
Throttle outputs compared to magnitude of vibration during each stage of flight with the Skylift V50 (Mugin 5 Pro) VTOL drone.
High thrust periods correspond with the greatest peaks in vibration measured. Trans 1 = Transition from hover to cruise. Trans 2 = Transition from cruise to hover. The RMS acceleration is calculated with as a 1 second sliding window and the mean is subtracted from the data.
Fig 8.
Octave spectra of resultant vibration (a) in the cargo bay of the Skylift V50 (Mugin 5 Pro) and (b) inside the Versapak.
Fig 9.
Elution profile of monomeric (a) Bevacizumab, (b) Trastuzumab and (c) Rituximab as received by Size Exclusion Chromatography.
Fig 10.
SE-HPLC peak area (%) of Bevacizumab of aggregates (HMWS) and fragments (LMWS) in different storage conditions (trial 2).
Data are shown as mean ± SD (n = 3).
Table 2.
Summary of DLS result of Bevacizumab at different storage conditions (trial 2).
Fig 11.
SE-HPLC peak area (%) of Trastuzumab of aggregates (HMWS) and fragments (LMWS) in different storage conditions.
Data are shown as mean ± SD (n = 3).
Table 3.
Summary of DLS result of Trastuzumab at different storage conditions.
Fig 12.
SE-HPLC peak area (%) of Rituximab of aggregates (HMWS) and fragments (LMWS) in different storage conditions.
Data are shown as mean ± SD (n = 3). Data are shown as mean ± SD (n = 3).
Table 4.
Summary of DLS result of Rituximab at different storage conditions.